

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**TERMINATION OF
THE SUBSCRIPTION AGREEMENTS
IN RELATION TO THE
ISSUE OF CONVERTIBLE BONDS UNDER GENERAL MANDATE
AND
RESUMPTION OF TRADING**

Reference is made to the announcement (the “**Announcement**”) of China NT Pharma Group Company Limited (the “**Company**”) dated 9 February 2026 in relation to the issue of convertible bonds under general mandate pursuant to the Subscription Agreements. Capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement unless the context otherwise requires.

**TERMINATION OF THE SUBSCRIPTION AGREEMENTS IN RELATION TO THE
ISSUE OF CONVERTIBLE BONDS**

The Board hereby announces that, following further discussions between the Company and the Subscribers regarding the terms and arrangements under the Subscription Agreements, and to ensure full compliance with the Listing Rules, the Company and each of the Subscribers entered into a termination agreement on 10 February 2026 (collectively, the “**Termination Agreements**”) to terminate the respective Subscription Agreement with effect from the date of the Termination Agreements.

As at the date of this announcement, Closing has not occurred and no Bonds and no Bond certificate have been issued or delivered to the Subscribers under the Subscription Agreements. No amount has been paid by the Subscribers to the Company under the Subscription Agreements and no set-offs pursuant to the Subscription Agreements have taken effect.

Pursuant to the Termination Agreements, the Subscription Agreements have ceased to have further force and effect with effect from the date thereof and each Party has irrevocably and unconditionally released and discharged the other Party and its respective directors, officers, employees, agents and representatives from all claims, demands, causes of action, liabilities, costs and expenses of any nature arising out of or in connection with the respective Subscription Agreement.

The Board considers that the termination of the Subscription Agreements has no material adverse impact on the business operations and financial position of the Group.

RESUMPTION OF TRADING

At the request of the Company, trading in the shares of the Company was halted with effect from 9:03 a.m. on 10 February 2026 pending the release of this announcement. An application has been made by the Company to the Stock Exchange for the resumption of trading in the shares of the Company with effect from 9:00 a.m. on 11 February 2026.

By order of the Board
China NT Pharma Group Company Limited
NG Tit
Chairman

Hong Kong, 10 February 2026

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng, Anna Ching Mei; the non-executive Directors are Dr. Qian Wei and Ms. Chin Yu; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Ng Ming Kwan and Dr. Zhao Yubiao.